Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine

NCT03901482 is registered in ClinicalTrials.gov with Satsuma Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03901482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03901482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 24, 2019
Completion date
August 13, 2020
Enrollment
1,201 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

migraine, migraine with aura, migraine without aura